Istradefylline Patent Expiration
Istradefylline is Used for managing off time in patients with Parkinson's disease undergoing L-DOPA therapy. It was first introduced by Kyowa Kirin Inc
Istradefylline Patents
Given below is the list of patents protecting Istradefylline, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Nourianz | US7727993 | Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy | Jan 28, 2028 | Kyowa Kirin |
| Nourianz | US8318201 | Method of stabilizing diarylvinylene compound | Sep 05, 2027 | Kyowa Kirin |
| Nourianz | US7541363 | Microcrystal |
Nov 13, 2024
(Expired) | Kyowa Kirin |
| Nourianz | US7727994 | Methods of treating patients suffering from movement disorders |
Jan 18, 2023
(Expired) | Kyowa Kirin |
Istradefylline's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Istradefylline:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Istradefylline for Parkinson Disease With Cognitive Impairment | Virginia Commonwealth University | NA |
COMPLETED
(Sep 1, 2026)
| PHASE2 |